ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer continued its full-court press last week to convince AstraZeneca shareholders that its takeover offer is in their best interest. In an investor presentation and an appearance before the U.K. Parliament, Pfizer CEO Ian C. Read tried to make the case that AstraZeneca, on its own, faces patent expirations and other business challenges. Pfizer hasn’t raised its $106 billion offer but indicated that “constructive engagement may lead to a transaction that AstraZeneca can recommend.” AstraZeneca responded that Pfizer came with no new proposals and is “making an opportunistic attempt to acquire a transformed AstraZeneca.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter